OncoSec Medical Inc (ONCSQ)

[hschlauch]

I am not sure whether or not they will report on more patients than what they did at SITC, but it is possible.

I am looking forward to the immune reponse data. We should be able to see for the first time how the combo treatment is impacting the TIL phenotype percentages. We had seen baseline levels reported at SITC, but no monitoring percentages were shared. Is immunopulse IL-12 elevating the PD-1/CTLA-4 hi TIL phenotype in activated CD8 tcells, thus priming immune cells for pembrolizumab? If so, how significant are those changes, and are the post treatment TIL phenotype levels exceeding that magic 20% threshold?